solute carrier family 2 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored SLC2AXP1 profile across patient tissues and cancer cell-line models. SLC2AXP1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, SLC2AXP1 is differentially expressed in 3, with the highest sampling consensus in KIRP. Additionally, SLC2AXP1 RNA expression shows 6,124 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUSC, KIRP, and STAD as cancer lineages where SLC2AXP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC2AXP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC2AXP1 survival associations across molecular data types. SLC2AXP1 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC2AXP1 RNA expression–survival associations across cancer types. High SLC2AXP1 expression shows unfavorable associations in LUSC, KICH, THYM, THCA and COAD, but favorable associations in OV. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for SLC2AXP1 RNA expression.
This table summarizes SLC2AXP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for SLC2AXP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC2AXP1 shows lower tumor expression in KICH and higher tumor expression in KIRP and KIRC. The KIRP box plot shows higher SLC2AXP1 RNA expression in tumor versus normal tissue (log2 FC = +0.054, t-test p = .004).
This table shows molecular features associated with SLC2AXP1 in patient tissues and cancer cell lines. In patient samples, SLC2AXP1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
